{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:31:17Z","timestamp":1790379077440,"version":"4.1.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Epidermolysis Bullosa (EB) is a rare genetic disorder characterised by extreme skin fragility, chronic wounds, and high morbidity. Current management is largely supportive, highlighting an urgent need for innovative therapeutic strategies. This review synthesises recent advances in topical therapies, including wound dressings, tissue-engineered skin, and molecular therapies, and evaluates the potential of these approaches to improve clinical outcomes and bridge the gap toward disease-modifying interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence acquisition<\/jats:title>\n                    <jats:p>Key developments in EB pathophysiology, advanced wound-care technologies, topical molecular therapies, and cell- or tissue-based interventions were examined through critical appraisal of relevant preclinical and clinical studies, with emphasis on translational potential and practical application.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Next-generation dressings incorporating hydrogels, extracellular matrix-mimetic scaffolds, nanoparticles, and smart-responsive systems demonstrate enhanced protection, moisture balance, and localised therapeutic delivery, supporting wound healing while minimising trauma. Topical molecular therapies\u2014including gene therapy, repurposed drugs, and bioactive natural compounds\u2014show proof-of-concept for symptomatic relief and potential disease modification. Cell- and tissue-based approaches, such as ex vivo gene-corrected keratinocyte grafts and cultured skin substitutes, offer durable regeneration but remain limited by cost and accessibility. Integration of these strategies, combined with patient-centred design and co-development, holds promise for improving functional outcomes and quality of life in EB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Advanced wound dressings, bioactive topical therapies, and tissue-engineered constructs represent complementary and translationally relevant approaches to EB care. Optimising the synergy between material-based and molecular strategies, alongside standardised clinical endpoints and long-term safety evaluation, is essential for bridging supportive care and future disease-modifying therapies, ultimately improving outcomes for patients with EB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40199-026-00601-5","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:38:36Z","timestamp":1775194716000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Innovations in topical epidermolysis bullosa treatment: integrating advanced dressings, bioactive therapies and tissue-engineered skin"],"prefix":"10.1007","volume":"34","author":[{"given":"Mandeep Kaur","family":"Marwah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirandeep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakil","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmony C. K.","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"issue":"1","key":"601_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41572-020-0210-0","volume":"6","author":"A Bardhan","year":"2020","unstructured":"Bardhan A, et al. Epidermolysis bullosa. Nat Reviews Disease Primers. 2020;6(1):78.","journal-title":"Nat Reviews Disease Primers"},{"key":"601_CR2","doi-asserted-by":"crossref","unstructured":"Prodinger C et al. Epidermolysis bullosa: Advances in research and treatment. 2019;28(10):1176\u20131189.","DOI":"10.1111\/exd.13979"},{"issue":"1","key":"601_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1750-1172-5-12","volume":"5","author":"J-D Fine","year":"2010","unstructured":"Fine J-D. Inherited epidermolysis bullosa. J Orphanet J rare Dis. 2010;5(1):12.","journal-title":"J Orphanet J rare Dis"},{"issue":"3","key":"601_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jaad.2009.03.052","volume":"61","author":"J-D Fine","year":"2009","unstructured":"Fine J-D, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. J Am Acad Dermatol. 2009;61(3):367\u201384.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"601_CR5","first-page":"18","volume":"27","author":"YY Kotalevskaya","year":"2023","unstructured":"Kotalevskaya YY, Stepanov VA. Molecular genetic basis of epidermolysis bullosa. Vavilovskii Zhurnal Genet Selektsii. 2023;27(1):18\u201327.","journal-title":"Vavilovskii Zhurnal Genet Selektsii"},{"issue":"6","key":"601_CR6","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jaad.2014.01.903","volume":"70","author":"J-D Fine","year":"2014","unstructured":"Fine J-D, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014;70(6):1103\u201326.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"601_CR7","first-page":"637","volume":"164","author":"M Bolling","year":"2011","unstructured":"Bolling M, et al. Mutations in KRT5 and KRT14 cause epidermolysis bullosa simplex in 75% of the patients. J Br J Dermatology. 2011;164(3):637\u201344.","journal-title":"J Br J Dermatology"},{"issue":"1","key":"601_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13023-021-01811-7","volume":"16","author":"JY Tang","year":"2021","unstructured":"Tang JY, et al. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa. J Orphanet J rare Dis. 2021;16(1):175.","journal-title":"J Orphanet J rare Dis"},{"issue":"1","key":"601_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1750-1172-9-76","volume":"9","author":"M El Hachem","year":"2014","unstructured":"El Hachem M, et al. Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa. Orphanet J Rare Dis. 2014;9(1):76.","journal-title":"Orphanet J Rare Dis"},{"key":"601_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.matbio.2013.07.007","volume":"33","author":"L Bruckner-Tuderman","year":"2014","unstructured":"Bruckner-Tuderman L, Has C. Disorders of the cutaneous basement membrane zone\u2014the paradigm of epidermolysis bullosa. J Matrix biology. 2014;33:29\u201334.","journal-title":"J Matrix biology"},{"issue":"3","key":"601_CR11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1346-8138.2009.00800.x","volume":"37","author":"D Sawamura","year":"2010","unstructured":"Sawamura D, Nakano H, Matsuzaki Y. Overview of epidermolysis bullosa. J Dermatol. 2010;37(3):214\u20139.","journal-title":"J Dermatol"},{"key":"601_CR12","unstructured":"So JY, Teng J. Epidermolysis Bullosa Simplex. University of Washington, Seattle, Seattle (WA); 1993."},{"issue":"22","key":"601_CR13","doi-asserted-by":"publisher","first-page":"5707","DOI":"10.3390\/ijms20225707","volume":"20","author":"AG Condorelli","year":"2019","unstructured":"Condorelli AG, et al. Epidermolysis Bullosa-Associated Squamous Cell Carcinoma: From Pathogenesis to Therapeutic Perspectives. Int J Mol Sci. 2019;20(22):5707.","journal-title":"Int J Mol Sci"},{"key":"601_CR14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.matbio.2018.04.001","volume":"71","author":"C Has","year":"2018","unstructured":"Has C, et al. Epidermolysis bullosa: Molecular pathology of connective tissue components in the cutaneous basement membrane zone. J Matrix Biology. 2018;71:313\u201329.","journal-title":"J Matrix Biology"},{"issue":"9","key":"601_CR15","first-page":"775","volume":"111","author":"R Torres-Iberico","year":"2020","unstructured":"Torres-Iberico R, et al. Kindler syndrome: a multidisciplinary management approach. J Actas Dermo-Sifiliogr\u00e1ficas. 2020;111(9):775\u201380.","journal-title":"J Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"601_CR16","doi-asserted-by":"crossref","unstructured":"Aamir M et al. Unique Dermatological and Systemic Manifestations in a Classic Pediatric Case of Kindler Syndrome: A Case Report and Literature Review. 2025;18:11795476251342637.","DOI":"10.1177\/11795476251342637"},{"issue":"8","key":"601_CR17","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1080\/21678707.2016.1207519","volume":"4","author":"L Youssefian","year":"2016","unstructured":"Youssefian L, et al. Kindler syndrome, an orphan disease of cell\/matrix adhesion in the skin \u2013 molecular genetics and therapeutic opportunities. Expert Opin Orphan Drugs. 2016;4(8):845\u201354.","journal-title":"Expert Opin Orphan Drugs"},{"issue":"10","key":"601_CR18","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.3390\/ijms22105104","volume":"22","author":"G Tartaglia","year":"2021","unstructured":"Tartaglia G, et al. Impaired wound healing, fibrosis, and cancer: the paradigm of recessive dystrophic epidermolysis bullosa. J Int J Mol Sci. 2021;22(10):5104.","journal-title":"J Int J Mol Sci"},{"key":"601_CR19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jdin.2023.02.016","volume":"11","author":"JE Mellerio","year":"2023","unstructured":"Mellerio JE, et al. Mapping the burden of severe forms of epidermolysis bullosa \u2013 Implications for patient management. JAAD Int. 2023;11:224\u201332.","journal-title":"JAAD Int"},{"issue":"3","key":"601_CR20","doi-asserted-by":"publisher","first-page":"110805","DOI":"10.1016\/j.humimm.2024.110805","volume":"85","author":"C Santucci","year":"2024","unstructured":"Santucci C, et al. Unravelling drivers of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa. Hum Immunol. 2024;85(3):110805.","journal-title":"Hum Immunol"},{"issue":"1","key":"601_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13023-022-02448-w","volume":"18","author":"C Liy-Wong","year":"2023","unstructured":"Liy-Wong C, et al. Consensus guidelines for diagnosis and management of anemia in epidermolysis bullosa. J Orphanet J rare Dis. 2023;18(1):38.","journal-title":"J Orphanet J rare Dis"},{"issue":"9","key":"601_CR22","doi-asserted-by":"publisher","first-page":"e0274072","DOI":"10.1371\/journal.pone.0274072","volume":"17","author":"G Rodari","year":"2022","unstructured":"Rodari G, et al. A single-centre study on predictors and determinants of pubertal delay and growth impairment in Epidermolysis Bullosa. PLoS ONE. 2022;17(9):e0274072.","journal-title":"PLoS ONE"},{"issue":"8","key":"601_CR23","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1054\/bjps.1998.9997","volume":"51","author":"M Eisenberg","year":"1998","unstructured":"Eisenberg M, Llewelyn D. Surgical management of hands in children with recessive dystrophic epidermolysis bullosa: use of allogeneic composite cultured skin grafts. Br J Plast Surg. 1998;51(8):608\u201313.","journal-title":"Br J Plast Surg"},{"issue":"6","key":"601_CR24","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/j.1365-4362.1994.tb04049.x","volume":"33","author":"S Ikeda","year":"1994","unstructured":"Ikeda S, Yaguchi H, Ogawa H. Successful surgical management and long-term follow-up of epidermolysis bullosa. Int J Dermatol. 1994;33(6):442\u20135.","journal-title":"Int J Dermatol"},{"key":"601_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/193293a0","volume":"193","author":"GD Winter","year":"1962","unstructured":"Winter GD. Formation of the scab and the rate of epithelization of superficial wounds in the skin of the young domestic pig. Nature. 1962;193:293\u20134.","journal-title":"Nature"},{"issue":"5","key":"601_CR26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ijnurstu.2003.12.009","volume":"41","author":"N Browne","year":"2004","unstructured":"Browne N, et al. Woundcare Research for Appropriate Products (WRAP): validation of the TELER method involving users. Int J Nurs Stud. 2004;41(5):559\u201371.","journal-title":"Int J Nurs Stud"},{"issue":"3","key":"601_CR27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1742-481X.2012.00973.x","volume":"10","author":"P Grocott","year":"2013","unstructured":"Grocott P, et al. Living in dressings and bandages: findings from workshops with people with Epidermolysis bullosa. Int Wound J. 2013;10(3):274\u201384.","journal-title":"Int Wound J"},{"issue":"6","key":"601_CR28","first-page":"574","volume":"12","author":"AGW Sandoval","year":"2025","unstructured":"Sandoval AGW, Badiavas EV. Towards Extracellular Vesicles in the Treatment of Epidermolysis Bullosa. Bioeng (Basel). 2025;12(6):574.","journal-title":"Bioeng (Basel)"},{"issue":"1","key":"601_CR29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12916-014-0178-2","volume":"12","author":"KR Goldschneider","year":"2014","unstructured":"Goldschneider KR, et al. Pain care for patients with epidermolysis bullosa: best care practice guidelines. BMC Med. 2014;12(1):178.","journal-title":"BMC Med"},{"key":"601_CR30","doi-asserted-by":"crossref","unstructured":"Moore RA et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. J Cochrane database Syst reviews, 2014;(4).","DOI":"10.1002\/14651858.CD007938.pub3"},{"issue":"6","key":"601_CR31","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1046\/j.1525-1470.1999.00120.x","volume":"16","author":"YK Chiu","year":"1999","unstructured":"Chiu YK, et al. Pain management of junctional epidermolysis bullosa in an 11-year\u2010old boy. J Pediatr dermatology. 1999;16(6):465\u20138.","journal-title":"J Pediatr dermatology"},{"issue":"1","key":"601_CR32","doi-asserted-by":"publisher","first-page":"2370424","DOI":"10.1080\/09546634.2024.2370424","volume":"35","author":"NS Jayawardena","year":"2024","unstructured":"Jayawardena NS, Wargon O, Tatian AH. Review: the spectrum of antimicrobial resistance in bacteria isolated from wounds of patients with epidermolysis bullosa. J Dermatological Treat. 2024;35(1):2370424.","journal-title":"J Dermatological Treat"},{"issue":"5","key":"601_CR33","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/0190-9622(90)70120-7","volume":"22","author":"JA Moy","year":"1990","unstructured":"Moy JA, et al. Mupirocin-resistant Staphylococcus aureus after long-term treatment of patients with epidermolysis bullosa. J J Am Acad Dermatology. 1990;22(5):893\u20135.","journal-title":"J J Am Acad Dermatology"},{"issue":"2","key":"601_CR34","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.det.2010.01.010","volume":"28","author":"L Haynes","year":"2010","unstructured":"Haynes L. Nutrition for children with epidermolysis bullosa. Dermatol Clin. 2010;28(2):289\u2013301. x.","journal-title":"Dermatol Clin"},{"issue":"1","key":"601_CR35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ijwd.2014.12.001","volume":"1","author":"SJE Hwang","year":"2015","unstructured":"Hwang SJE, et al. Prevalence of anemia in patients with epidermolysis bullosa registered in Australia. Int J Womens Dermatol. 2015;1(1):37\u201340.","journal-title":"Int J Womens Dermatol"},{"issue":"2","key":"601_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1046\/j.1365-277X.1998.00090.x","volume":"11","author":"L Haynes","year":"1998","unstructured":"Haynes L. Nutritional support for children with epidermolysis bullosa. J Hum Nutr Dietetics. 1998;11(2):163\u201373.","journal-title":"J Hum Nutr Dietetics"},{"issue":"1","key":"601_CR37","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13023-023-02870-8","volume":"18","author":"MP Popenhagen","year":"2023","unstructured":"Popenhagen MP, et al. Consensus-based guidelines for the provision of palliative and end-of-life care for people living with epidermolysis bullosa. Orphanet J Rare Dis. 2023;18(1):268.","journal-title":"Orphanet J Rare Dis"},{"key":"601_CR38","doi-asserted-by":"crossref","unstructured":"Wu YH, Sun FK. Family caregivers\u2019 lived experiences of caring for epidermolysis bullosa patients: a phenomenological study. J Clin Nurs. 2020;29(9\u201310):1552\u201360.","DOI":"10.1111\/jocn.15209"},{"issue":"1","key":"601_CR39","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s13023-022-02419-1","volume":"17","author":"A Angelis","year":"2022","unstructured":"Angelis A, Mellerio JE, Kanavos P. Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life study. Orphanet J Rare Dis. 2022;17(1):346.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"601_CR40","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41573-022-00476-6","volume":"21","author":"CJ Bashor","year":"2022","unstructured":"Bashor CJ, et al. Engineering the next generation of cell-based therapeutics. Nat Rev Drug Discovery. 2022;21(9):655\u201375.","journal-title":"Nat Rev Drug Discovery"},{"issue":"1680","key":"601_CR41","first-page":"20150017","volume":"370","author":"NM Mount","year":"2015","unstructured":"Mount NM, et al. Cell-based therapy technology classifications and translational challenges. Nat Rev Drug Discovery. 2015;370(1680):20150017.","journal-title":"Nat Rev Drug Discovery"},{"key":"601_CR42","doi-asserted-by":"publisher","first-page":"1598145","DOI":"10.3389\/fddev.2025.1598145","volume":"5","author":"L Li","year":"2025","unstructured":"Li L. Gene hydrogel platforms for targeted skin therapy: bridging hereditary disorders, chronic wounds, and immune related skin diseases. J Front Drug Delivery. 2025;5:1598145.","journal-title":"J Front Drug Delivery"},{"issue":"7","key":"601_CR43","doi-asserted-by":"publisher","first-page":"2100028","DOI":"10.1002\/adtp.202100028","volume":"4","author":"AI Barbosa","year":"2021","unstructured":"Barbosa AI, et al. Hydrogels: a promising vehicle for the topical management of atopic dermatitis. J Adv Ther. 2021;4(7):2100028.","journal-title":"J Adv Ther"},{"issue":"1","key":"601_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.12968\/jowc.2019.28.1.5","volume":"28","author":"T Graham","year":"2019","unstructured":"Graham T, et al. Iterative codesign and testing of a novel dressing glove for epidermolysis bullosa. J Wound Care. 2019;28(1):5\u201314.","journal-title":"J Wound Care"},{"issue":"8","key":"601_CR45","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.bjps.2009.06.038","volume":"63","author":"J Jutkiewicz","year":"2010","unstructured":"Jutkiewicz J, Noszczyk BH, Wrobel M. The use of Biobrane for hand surgery in Epidermolysis bullosa. J Plast Reconstr Aesthetic Surg. 2010;63(8):1305\u201311.","journal-title":"J Plast Reconstr Aesthetic Surg"},{"issue":"7","key":"601_CR46","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.3390\/ijms25073849","volume":"25","author":"G Olteanu","year":"2024","unstructured":"Olteanu G, et al. Advancements in regenerative hydrogels in skin wound treatment: a comprehensive review. J Int J Mol Sci. 2024;25(7):3849.","journal-title":"J Int J Mol Sci"},{"key":"601_CR47","doi-asserted-by":"crossref","unstructured":"Duong TKN et al. Hydrogel-Based Smart Materials for Wound Healing and Sensing. J Aggreg, 2025;6:e70047.","DOI":"10.1002\/agt2.70047"},{"issue":"11","key":"601_CR48","doi-asserted-by":"publisher","first-page":"11023","DOI":"10.48048\/tis.2025.11023","volume":"22","author":"MD Rossary","year":"2025","unstructured":"Rossary MD, et al. Tailoring Strategy of Chitosan-Based Hydrogel for Improving Wound Healing: A Systematic Review. Trends Sci. 2025;22(11):11023.","journal-title":"Trends Sci"},{"issue":"4","key":"601_CR49","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/01.ASW.0000428864.72412.b7","volume":"26","author":"E Pope","year":"2013","unstructured":"Pope E, et al. Epidermolysis Bullosa and Chronic Wounds: A Model for Wound Bed Preparation of Fragile Skin. Adv Skin Wound Care. 2013;26(4):177\u201388.","journal-title":"Adv Skin Wound Care"},{"issue":"1","key":"601_CR50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/md21010014","volume":"21","author":"Q He","year":"2022","unstructured":"He Q, et al. Advances in Algin and Alginate-Hybrid Materials for Drug Delivery and Tissue Engineering. Mar Drugs. 2022;21(1):14.","journal-title":"Mar Drugs"},{"key":"601_CR51","doi-asserted-by":"crossref","unstructured":"Pintilei PS et al. The Role of Natural Hydrogels in Enhancing Wound Healing: From Biomaterials to Bioactive Therapies. Pharmaceutics. 2025;17(10):1243.","DOI":"10.3390\/pharmaceutics17101243"},{"issue":"2","key":"601_CR52","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000276303","volume":"44","author":"O Goertz","year":"2010","unstructured":"Goertz O, et al. Clinical safety and efficacy of a novel thermoreversible polyhexanide-preserved wound covering gel. Eur Surg Res. 2010;44(2):96\u2013101.","journal-title":"Eur Surg Res"},{"issue":"34","key":"601_CR53","doi-asserted-by":"publisher","first-page":"9984","DOI":"10.1002\/anie.201604827","volume":"55","author":"MD Konieczynska","year":"2016","unstructured":"Konieczynska MD, et al. On-Demand Dissolution of a Dendritic Hydrogel-based Dressing for Second-Degree Burn Wounds through Thiol-Thioester Exchange Reaction. Angew Chem Int Ed Engl. 2016;55(34):9984\u20137.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1","key":"601_CR54","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10570-021-04287-7","volume":"29","author":"CR Reshmi","year":"2022","unstructured":"Reshmi CR, et al. Poly \u025b-caprolactone\/nanostarch composite nanofibrous wound dressing with antibacterial property and pH stimulus drug release. Cellulose. 2022;29(1):427\u201343.","journal-title":"Cellulose"},{"issue":"2","key":"601_CR55","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/pat.4481","volume":"30","author":"F-L He","year":"2019","unstructured":"He F-L, et al. Controlled release of antibiotics from poly-\u03b5-caprolactone\/polyethylene glycol wound dressing fabricated by direct-writing melt electrospinning. Polym Adv Technol. 2019;30(2):425\u201334.","journal-title":"Polym Adv Technol"},{"issue":"1","key":"601_CR56","first-page":"2025170","volume":"2022","author":"BF Adamu","year":"2022","unstructured":"Adamu BF, et al. Self-Responsive Electrospun Nanofibers Wound Dressings: The Future of Wound Care. Adv Mater Sci Eng. 2022;2022(1):2025170.","journal-title":"Adv Mater Sci Eng"},{"key":"601_CR57","doi-asserted-by":"crossref","unstructured":"Mirzapoor A, et al. A Review of Advanced and Smart Nano Wound Dressings Based on Investigating the Function of Hybrid Nanosystems in Wound Monitoring and Antimicrobial Activity. J J Shahid Sadoughi Univ Med Sci. 2024.","DOI":"10.18502\/ssu.v32i7.16565"},{"issue":"8","key":"601_CR58","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1002\/jbm.b.32785","volume":"100","author":"B Song","year":"2012","unstructured":"Song B, Wu C, Chang J. Controllable delivery of hydrophilic and hydrophobic drugs from electrospun poly(lactic-co-glycolic acid)\/mesoporous silica nanoparticles composite mats. J Biomed Mater Res B Appl Biomater. 2012;100(8):2178\u201386.","journal-title":"J Biomed Mater Res B Appl Biomater"},{"issue":"2","key":"601_CR59","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","volume":"161","author":"F Danhier","year":"2012","unstructured":"Danhier F, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505\u201322.","journal-title":"J Control Release"},{"issue":"2","key":"601_CR60","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1080\/08982104.2019.1604746","volume":"30","author":"M Marwah","year":"2020","unstructured":"Marwah M, et al. Intracellular uptake of EGCG-loaded deformable controlled release liposomes for skin cancer. J Liposome Res. 2020;30(2):136\u201349.","journal-title":"J Liposome Res"},{"issue":"2","key":"601_CR61","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s11095-021-03164-z","volume":"39","author":"MK Marwah","year":"2022","unstructured":"Marwah MK, et al. Transdermal Delivery of a Hydrogen Sulphide Donor, ADT-OH Using Aqueous Gel Formulations for the Treatment of Impaired Vascular Function: an Ex Vivo Study. Pharm Res. 2022;39(2):341\u201352.","journal-title":"Pharm Res"},{"key":"601_CR62","first-page":"147","volume-title":"Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging","author":"S Parveen","year":"2012","unstructured":"Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Volume 8. Nanomedicine: Nanotechnology, Biology and Medicine; 2012. pp. 147\u201366. 2."},{"issue":"4","key":"601_CR63","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41591-022-01737-y","volume":"28","author":"I Gurevich","year":"2022","unstructured":"Gurevich I, et al. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. J Nat Med. 2022;28(4):780\u20138.","journal-title":"J Nat Med"},{"issue":"24","key":"601_CR64","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","volume":"387","author":"SV Guide","year":"2022","unstructured":"Guide SV, et al. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa. N Engl J Med. 2022;387(24):2211\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"601_CR65","doi-asserted-by":"publisher","first-page":"2350232","DOI":"10.1080\/09546634.2024.2350232","volume":"35","author":"AS Paller","year":"2024","unstructured":"Paller AS, et al. Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa. J Dermatological Treat. 2024;35(1):2350232.","journal-title":"J Dermatological Treat"},{"issue":"3","key":"601_CR66","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1001\/jamadermatol.2023.5857","volume":"160","author":"AJN Raymakers","year":"2024","unstructured":"Raymakers AJN, et al. Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa. JAMA Dermatology. 2024;160(3):297\u2013302.","journal-title":"JAMA Dermatology"},{"issue":"1","key":"601_CR67","doi-asserted-by":"publisher","first-page":"e86147","DOI":"10.1371\/journal.pone.0086147","volume":"9","author":"S Ebeling","year":"2014","unstructured":"Ebeling S, et al. From a Traditional Medicinal Plant to a Rational Drug: Understanding the Clinically Proven Wound Healing Efficacy of Birch Bark Extract. PLoS ONE. 2014;9(1):e86147.","journal-title":"PLoS ONE"},{"issue":"1","key":"601_CR68","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/bjd\/ljac001","volume":"188","author":"JS Kern","year":"2022","unstructured":"Kern JS, et al. Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study. Br J Dermatol. 2022;188(1):12\u201321.","journal-title":"Br J Dermatol"},{"key":"601_CR69","unstructured":"InMed. InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa. 2023 [cited 2025 18\/12\/2025]; Available from: https:\/\/www.inmedpharma.com\/news_release\/inmed-pharmaceuticals-inc-announces-results-from-a-phase-2-clinical-trial-in-epidermolysis-bullosa\/"},{"issue":"2","key":"601_CR70","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/epi.13973","volume":"59","author":"MJ Brodie","year":"2018","unstructured":"Brodie MJ, Ben-Menachem E. Cannabinoids for epilepsy: what do we know and where do we go? J Epilepsia. 2018;59(2):291\u20136.","journal-title":"J Epilepsia"},{"issue":"24","key":"601_CR71","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1001\/jama.2015.6199","volume":"313","author":"KP Hill","year":"2015","unstructured":"Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. J Jama. 2015;313(24):2474\u201383.","journal-title":"J Jama"},{"issue":"1","key":"601_CR72","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1365-2222.2011.03791.x","volume":"42","author":"C Potenzieri","year":"2012","unstructured":"Potenzieri C, Undem BJ. Basic mechanisms of itch. J Clin Experimental Allergy. 2012;42(1):8\u201319.","journal-title":"J Clin Experimental Allergy"},{"key":"601_CR73","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000446011","volume":"50","author":"E Carstens","year":"2016","unstructured":"Carstens E, Akiyama T. Central mechanisms of itch. J Curr Probl dermatology. 2016;50:11.","journal-title":"J Curr Probl dermatology"},{"key":"601_CR74","unstructured":"Mancini A, et al. INM-755 Cannabinol Cream Demonstrates Anti-itch Activity in Patients with Epidermolysis Bullosa, in 12th World Congress on Itch. World Congress on Itch Miami, FL; 2023."},{"key":"601_CR75","doi-asserted-by":"crossref","unstructured":"Zhang N et al. Effect of ropivacaine on peripheral neuropathy in streptozocin diabetes-induced rats through TRPV1-CGRP pathway. Biosci Rep. 2019;39(11).","DOI":"10.1042\/BSR20190817"},{"issue":"6","key":"601_CR76","first-page":"529","volume":"68","author":"N Lo Martire","year":"2002","unstructured":"Lo Martire N, et al. [Topical anesthesia for cataract surgery with phacoemulsification: lidocaine 2% vs ropivacaine 1%. Preliminary results]. Minerva Anestesiol. 2002;68(6):529\u201335.","journal-title":"Minerva Anestesiol"},{"issue":"3","key":"601_CR77","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/bjd.19551","volume":"184","author":"E Moreno Artero","year":"2021","unstructured":"Moreno Artero E, et al. Efficacy of topical ropivacaine in children and young adults with hereditary epidermolysis bullosa. Br J Dermatol. 2021;184(3):550\u20132.","journal-title":"Br J Dermatol"},{"key":"601_CR78","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1750-1172-8-69","volume":"8","author":"V Wally","year":"2013","unstructured":"Wally V, et al. Topical diacerein for epidermolysis bullosa: a randomized controlled pilot study. Orphanet J Rare Dis. 2013;8:69.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"601_CR79","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.jaad.2018.01.019","volume":"78","author":"V Wally","year":"2018","unstructured":"Wally V, et al. Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2\/3 randomized, placebo-controlled, double-blind clinical trial. J Am Acad Dermatol. 2018;78(5):892\u2013e9017.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"601_CR80","doi-asserted-by":"publisher","first-page":"599","DOI":"10.36849\/JDD.7108","volume":"22","author":"J Teng","year":"2023","unstructured":"Teng J, et al. Diacerein 1% Ointment for the Treatment of Epidermolysis Bullosa Simplex: A Randomized, Controlled Trial. J Drugs Dermatol. 2023;22(6):599\u2013604.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"601_CR81","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/j.jid.2023.03.604","volume":"143","author":"AN Johnson","year":"2023","unstructured":"Johnson AN, et al. 597 Interim results of a phase I\/II, closed label, randomized pilot study for the safety and efficacy of TolaSure gel, 5% w\/w targeting aggregated mutant keratin in severe epidermolysis bullosa simplex (TAMES). J Invest Dermatology. 2023;143(5):S102.","journal-title":"J Invest Dermatology"},{"issue":"8","key":"601_CR82","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1172\/JCI92707","volume":"127","author":"DT Woodley","year":"2017","unstructured":"Woodley DT, et al. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients. J Clin Investig. 2017;127(8):3028\u201338.","journal-title":"J Clin Investig"},{"issue":"2","key":"601_CR83","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/jvc2.343","volume":"3","author":"\u00d8 Sandanger","year":"2024","unstructured":"Sandanger \u00d8, et al. Nonintensive topical gentamicin treatment of patients with severe epidermolysis bullosa caused by nonsense mutations. JEADV Clin Pract. 2024;3(2):536\u201346.","journal-title":"JEADV Clin Pract"},{"key":"601_CR84","unstructured":"Premier Specialists A. Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study. 2017 [cited 2025; NCT03016715]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03016715"},{"issue":"11","key":"601_CR85","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1517\/14656566.2.11.1903","volume":"2","author":"BD Kahan","year":"2001","unstructured":"Kahan BD. Sirolimus: a comprehensive review. Expert Opin Pharmacother. 2001;2(11):1903\u201317.","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"601_CR86","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1007\/s00405-022-07378-8","volume":"279","author":"S Wiegand","year":"2022","unstructured":"Wiegand S, Dietz A, Wichmann G. Efficacy of sirolimus in children with lymphatic malformations of the head and neck. J Eur Archives Oto-Rhino-Laryngology. 2022;279(8):3801\u201310.","journal-title":"J Eur Archives Oto-Rhino-Laryngology"},{"issue":"2","key":"601_CR87","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.jid.2021.07.170","volume":"142","author":"GH Lee","year":"2022","unstructured":"Lee GH, et al. Transcriptomic Repositioning Analysis Identifies mTOR Inhibitor as Potential Therapy for Epidermolysis Bullosa Simplex. J Invest Dermatol. 2022;142(2):382\u20139.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"601_CR88","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3390\/cells12121671","volume":"12","author":"T Roy","year":"2023","unstructured":"Roy T, et al. The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds. Cells. 2023;12(12):1671.","journal-title":"Cells"},{"issue":"7680","key":"601_CR89","first-page":"327","volume":"551","author":"T Hirsch","year":"2017","unstructured":"Hirsch T, et al. Regeneration of the entire human epidermis using transgenic stem cells. J Nat Med. 2017;551(7680):327\u201332.","journal-title":"J Nat Med"},{"issue":"24","key":"601_CR90","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1056\/NEJMoa2108544","volume":"385","author":"M Kueckelhaus","year":"2021","unstructured":"Kueckelhaus M, et al. Transgenic epidermal cultures for junctional epidermolysis bullosa\u20145-year outcomes. J New Engl J Med. 2021;385(24):2264\u201370.","journal-title":"J New Engl J Med"},{"issue":"17","key":"601_CR91","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1001\/jama.2016.15588","volume":"316","author":"Z Siprashvili","year":"2016","unstructured":"Siprashvili Z, et al. Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa. J Jama. 2016;316(17):1808\u201317.","journal-title":"J Jama"},{"issue":"1","key":"601_CR92","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/s13023-022-02546-9","volume":"17","author":"JY So","year":"2022","unstructured":"So JY, et al. Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2022;17(1):377.","journal-title":"Orphanet J Rare Dis"},{"issue":"10499","key":"601_CR93","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0140-6736(25)00778-0","volume":"406","author":"JY Tang","year":"2025","unstructured":"Tang JY, et al. Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial. Lancet. 2025;406(10499):163\u201373.","journal-title":"Lancet"},{"issue":"11","key":"601_CR94","doi-asserted-by":"publisher","first-page":"e126243","DOI":"10.1172\/jci.insight.126243","volume":"4","author":"SM Lwin","year":"2019","unstructured":"Lwin SM, et al. Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa. J JCI insight. 2019;4(11):e126243.","journal-title":"J JCI insight"},{"issue":"10","key":"601_CR95","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/archderm.136.10.1225","volume":"136","author":"AF Falabella","year":"2000","unstructured":"Falabella AF, et al. Tissue-engineered skin (Apligraf) in the healing of patients with epidermolysis bullosa wounds. Arch Dermatol. 2000;136(10):1225\u201330.","journal-title":"Arch Dermatol"},{"key":"601_CR96","first-page":"467","volume-title":"5.534 - Skin Tissue Engineering, in Comprehensive Biomaterials","author":"Q Zeng","year":"2011","unstructured":"Zeng Q, et al. 5.534 - Skin Tissue Engineering, in Comprehensive Biomaterials. Oxford: Elsevier; 2011. pp. 467\u201399. P. Ducheyne, Editor."},{"issue":"9","key":"601_CR97","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1089\/ten.2006.12.2407","volume":"12","author":"M Ehrenreich","year":"2006","unstructured":"Ehrenreich M, Ruszczak Z. Update on tissue-engineered biological dressings. J Tissue Eng. 2006;12(9):2407\u201324.","journal-title":"J Tissue Eng"},{"issue":"5","key":"601_CR98","first-page":"600","volume":"60","author":"CC Compton","year":"1989","unstructured":"Compton CC, et al. Skin regenerated from cultured epithelial autografts on full-thickness burn wounds from 6 days to 5 years after grafting. A light, electron microscopic and immunohistochemical study. Lab Invest. 1989;60(5):600\u201312.","journal-title":"Lab Invest"},{"issue":"15","key":"601_CR99","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.3390\/cells11152439","volume":"11","author":"P Kolimi","year":"2022","unstructured":"Kolimi P, et al. Innovative Treatment Strategies to Accelerate Wound Healing: Trajectory and Recent Advancements. Cells. 2022;11(15):2439.","journal-title":"Cells"},{"issue":"5","key":"601_CR100","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s13555-021-00578-w","volume":"11","author":"M Nita","year":"2021","unstructured":"Nita M, et al. Review of the Latest Methods of Epidermolysis Bullosa and Other Chronic Wounds Treatment Including BIOOPA Dressing. Dermatology Therapy. 2021;11(5):1469\u201380.","journal-title":"Dermatology Therapy"},{"key":"601_CR101","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.actbio.2016.11.017","volume":"49","author":"X Zhao","year":"2017","unstructured":"Zhao X, et al. Cell infiltrative hydrogel fibrous scaffolds for accelerated wound healing. Acta Biomater. 2017;49:66\u201377.","journal-title":"Acta Biomater"},{"key":"601_CR102","doi-asserted-by":"crossref","unstructured":"Nadelmann E, Czernik A. Wound care in immunobullous disease. J Autoimmune Bullous Dis. 2018;213\u201340.","DOI":"10.5772\/intechopen.71937"},{"issue":"11","key":"601_CR103","doi-asserted-by":"publisher","first-page":"482","DOI":"10.12968\/jowc.2008.17.11.31476","volume":"17","author":"L Ly","year":"2008","unstructured":"Ly L, Su J. Dressings used in epidermolysis bullosa blister wounds: a review. J J Wound Care. 2008;17(11):482\u201390.","journal-title":"J J Wound Care"},{"issue":"1","key":"601_CR104","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2174\/1877912304666140708184013","volume":"4","author":"AC Manoukian","year":"2014","unstructured":"Manoukian AC. Polymeric Nanoparticles to Combat Squamous Cell Carcinomas in Patients with Dystrophic Epidermolysis Bullosa. Recent Pat Nanomed. 2014;4(1):15\u201324.","journal-title":"Recent Pat Nanomed"},{"issue":"7","key":"601_CR105","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/adhm.201300519","volume":"3","author":"M Yang","year":"2014","unstructured":"Yang M, et al. Vaginal Delivery of Paclitaxel via Nanoparticles with Non-Mucoadhesive Surfaces Suppresses Cervical Tumor Growth. Adv Healthc Mater. 2014;3(7):1044\u201352.","journal-title":"Adv Healthc Mater"},{"issue":"27","key":"601_CR106","doi-asserted-by":"publisher","first-page":"22235","DOI":"10.1021\/acsami.7b05359","volume":"9","author":"C-C Chou","year":"2017","unstructured":"Chou C-C, et al. Molecular Elucidation of Biological Response to Mesoporous Silica Nanoparticles in Vitro and in Vivo. ACS Appl Mater Interfaces. 2017;9(27):22235\u201351.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"3","key":"601_CR107","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/biomimetics3030022","volume":"3","author":"E Rascol","year":"2018","unstructured":"Rascol E, et al. Biosafety of Mesoporous Silica Nanoparticles. Biomimetics (Basel). 2018;3(3):22.","journal-title":"Biomimetics (Basel)"},{"key":"601_CR108","unstructured":"Kempler C. FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa 2023 [cited 2025 1\/12\/2025]; Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-topical-gene-therapy-treatment-wounds-patients-dystrophic-epidermolysis-bullosa"},{"issue":"3","key":"601_CR109","first-page":"7","volume":"24","author":"AL Limmer","year":"2019","unstructured":"Limmer AL, et al. Topical Diacerein Ointment for Epidermolysis Bullosa Simplex: A Review. Skin Therapy Lett. 2019;24(3):7\u20139.","journal-title":"Skin Therapy Lett"},{"issue":"8","key":"601_CR110","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1016\/j.jid.2024.06.600","volume":"144","author":"K McGuire","year":"2024","unstructured":"McGuire K, et al. 584 Autophagic resistance in severe EBS is overcome by small allosteric mTOR inhibitor. J Invest Dermatology. 2024;144(8):S102.","journal-title":"J Invest Dermatology"},{"key":"601_CR111","unstructured":"Abeona Therapeutics IZEVASKYN. 2025 [cited 2025 05\/12\/2025]; Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/zevaskyn"},{"issue":"1","key":"601_CR112","first-page":"210150","volume":"2010","author":"I Juhasz","year":"2010","unstructured":"Juhasz I, et al. Long-Term Followup of Dermal Substitution with Acellular Dermal Implant in Burns and Postburn Scar Corrections. Clin Study. 2010;2010(1):210150.","journal-title":"Clin Study"},{"issue":"4","key":"601_CR113","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1755-148X.2009.00581.x","volume":"22","author":"MA Tran","year":"2009","unstructured":"Tran MA, Watts RJ, Robertson GP. Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell Melanoma Res. 2009;22(4):388\u201399.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"3","key":"601_CR114","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S1748-0132(07)70084-1","volume":"2","author":"M Arruebo","year":"2007","unstructured":"Arruebo M, et al. Magnetic nanoparticles for drug delivery. Nano Today. 2007;2(3):22\u201332.","journal-title":"Nano Today"},{"key":"601_CR115","doi-asserted-by":"publisher","first-page":"100031","DOI":"10.1016\/j.onano.2021.100031","volume":"5","author":"Y Mu","year":"2021","unstructured":"Mu Y, et al. Advances in pH-responsive drug delivery systems. J OpenNano. 2021;5:100031.","journal-title":"J OpenNano"},{"issue":"8","key":"601_CR116","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.3390\/ijms23084421","volume":"23","author":"M Sobczak","year":"2022","unstructured":"Sobczak M. Enzyme-responsive hydrogels as potential drug delivery systems\u2014state of knowledge and future prospects. J Int J Mol Sci. 2022;23(8):4421.","journal-title":"J Int J Mol Sci"},{"key":"601_CR117","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.matbio.2022.04.007","volume":"110","author":"N Harvey","year":"2022","unstructured":"Harvey N, et al. Pathomechanisms of epidermolysis bullosa: Beyond structural proteins. Matrix Biol. 2022;110:91\u2013105.","journal-title":"Matrix Biol"},{"issue":"9","key":"601_CR118","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/1346-8138.14489","volume":"45","author":"E Proksch","year":"2018","unstructured":"Proksch E. pH in nature, humans and skin. J Dermatol. 2018;45(9):1044\u201352.","journal-title":"J Dermatol"},{"issue":"25","key":"601_CR119","doi-asserted-by":"publisher","first-page":"2201620","DOI":"10.1002\/smll.202201620","volume":"18","author":"H Dong","year":"2022","unstructured":"Dong H, et al. Smart polycationic hydrogel dressing for dynamic wound healing. J Small. 2022;18(25):2201620.","journal-title":"J Small"},{"key":"601_CR120","doi-asserted-by":"crossref","unstructured":"Marwah MK et al. Formulation and In Vitro Characterisation of Withaferin A-Loaded Liposomal Gels for the Topical Management of Chronic Inflammatory Skin Conditions. Br J Biomed Sci. 2025;82\u201314847.","DOI":"10.3389\/bjbs.2025.14847"},{"issue":"3","key":"601_CR121","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/gerona\/glv043","volume":"71","author":"MH Park","year":"2016","unstructured":"Park MH, et al. Effects of MHY908, a new synthetic PPAR\u03b1\/\u03b3 dual agonist, on inflammatory responses and insulin resistance in aged rats. J Journals Gerontol Ser A: Biomedical Sci Med Sci. 2016;71(3):300\u20139.","journal-title":"J Journals Gerontol Ser A: Biomedical Sci Med Sci"},{"issue":"15","key":"601_CR122","doi-asserted-by":"publisher","first-page":"8102","DOI":"10.3390\/ijms25158102","volume":"25","author":"M Fern\u00e1ndez-Guarino","year":"2024","unstructured":"Fern\u00e1ndez-Guarino M, Gonz\u00e1lez-Garc\u00eda A, Mart\u00ednez AB. Exploring New Frontiers: Innovations and Therapeutic Targets in Dermatology. J Int J Mol Sci. 2024;25(15):8102.","journal-title":"J Int J Mol Sci"},{"issue":"3","key":"601_CR123","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/exd.14484","volume":"31","author":"CM Popp","year":"2022","unstructured":"Popp CM, et al. Future applications of 3D bioprinting: A promising technology for treating recessive dystrophic epidermolysis bullosa. Exp Dermatol. 2022;31(3):384\u201392.","journal-title":"Exp Dermatol"},{"key":"601_CR124","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.actbio.2019.08.045","volume":"101","author":"S Singh","year":"2020","unstructured":"Singh S, et al. In situ bioprinting\u2013bioprinting from benchside to bedside? J Acta Biomater. 2020;101:14\u201325.","journal-title":"J Acta Biomater"},{"issue":"28","key":"601_CR125","doi-asserted-by":"publisher","first-page":"23560","DOI":"10.1021\/acsami.8b05853","volume":"10","author":"D Chouhan","year":"2018","unstructured":"Chouhan D, et al. Recombinant spider silk functionalized silkworm silk matrices as potential bioactive wound dressings and skin grafts. J ACS Appl Mater. 2018;10(28):23560\u201372.","journal-title":"J ACS Appl Mater"},{"issue":"2","key":"601_CR126","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1096\/fj.13-238527","volume":"28","author":"J Devalliere","year":"2014","unstructured":"Devalliere J, et al. Sustained delivery of proangiogenic microRNA-132 by nanoparticle transfection improves endothelial cell transplantation. FASEB J. 2014;28(2):908\u201322.","journal-title":"FASEB J"},{"key":"601_CR127","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.actbio.2018.03.008","volume":"72","author":"J Guo","year":"2018","unstructured":"Guo J, et al. Development of tannin-inspired antimicrobial bioadhesives. Acta Biomater. 2018;72:35\u201344.","journal-title":"Acta Biomater"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00601-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-026-00601-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00601-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:26:43Z","timestamp":1781645203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-026-00601-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":127,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["601"],"URL":"https:\/\/doi.org\/10.1007\/s40199-026-00601-5","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"ChatGPT (GPT-5 mini) was used to assist with language editing and improving clarity of the manuscript. All scientific content, interpretations, and conclusions remain solely those of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of generative AI"}}],"article-number":"22"}}